Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Ovarian Neoplasms 44 Lung Neoplasms 29 Neuroblastoma 24 Small Cell Lung Carcinoma 21 Carcinoma, Ovarian Epithelial 19 Fallopian Tube Neoplasms 17 Neoplasms 14 Brain Neoplasms 14 Uterine Cervical Neoplasms 11 Leukemia, Myeloid, Acute 11 Leukemia 11 Retinoblastoma 10 Glioma 9 Recurrence 8 Sarcoma 7 Precursor Cell Lymphoblastic Leukemia-Lymphoma 7 Lymphoma 7 Central Nervous System Neoplasms 7 Sarcoma, Ewing 6 Neoplasm Metastasis 6 Lymphoma, Follicular 6 Unspecified Adult Solid Tumor, Protocol Specific 5 Osteosarcoma 5 Gliosarcoma 5 Glioblastoma 5 Endometrial Neoplasms 5 Burkitt Lymphoma 5 Blast Crisis 5 Astrocytoma 5 Wilms Tumor 4

Interventions

Surveys and Questionnaires 7 Standard of Care 5 Sirolimus 5 Bevacizumab 5 temsirolimus 4 Interviews as Topic 4 Paclitaxel 3 olaparib 2 Vorinostat 2 Olanzapine 2 Magnetic Resonance Spectroscopy 2 Gemcitabine 2 Everolimus 2 Erlotinib Hydrochloride 2 Dasatinib 2 Cetuximab 2 zaleplon 1 vistusertib 1 tilsotolimod 1 pazopanib 1 olanzapine-fluoxetine combination 1 nimotuzumab 1 liposomal doxorubicin 1 capivasertib 1 apatinib 1 Videotape Recording 1 Vemurafenib 1 Valproic Acid 1 Trastuzumab 1 Topotecan 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Advanced Cancer × Topotecan × Clear all

NCT00770731 2013-02-13

Study of Temsirolimus, Topotecan, and Bortezomib

M.D. Anderson Cancer Center

Phase 1 Completed

Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡